Skip to Main Content

Paper Details

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
J Clin Oncol
116
2017
CA-125, FTC, Familial Ovarian Cancer, OC, Ovarian Cancer, Participants, Women, cancer, cancers, fallopian tube cancer, interval, occult cancers, ovarian cancer, patients, serum cancer antigen 125, women
Author NameAffiliation
Elizabeth BenjaminUniversity College London Elizabeth Garrett Anderson Institute for Women's Health Elizabeth Benjamin, University College London Naveena Singh, Barts Health National Health Service Trust Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London Anne Dawnay, University College London Hospital James Mackay, The University College London Cancer Institute, University of Manchester, St Mary's Hospital Manchester, Southampton General Hospital, Massachusetts General Hospital and Harvard Medical School, University of New South Wales Australia
Naveena SinghUniversity College London Elizabeth Garrett Anderson Institute for Women's Health Elizabeth Benjamin, University College London Naveena Singh, Barts Health National Health Service Trust Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London Anne Dawnay, University College London Hospital James Mackay, The University College London Cancer Institute, University of Manchester, St Mary's Hospital Manchester, Southampton General Hospital, Massachusetts General Hospital and Harvard Medical School, University of New South Wales Australia
Steven J SkatesUniversity College London Elizabeth Garrett Anderson Institute for Women's Health Elizabeth Benjamin, University College London Naveena Singh, Barts Health National Health Service Trust Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London Anne Dawnay, University College London Hospital James Mackay, The University College London Cancer Institute, University of Manchester, St Mary's Hospital Manchester, Southampton General Hospital, Massachusetts General Hospital and Harvard Medical School, University of New South Wales Australia
Usha MenonUniversity College London Elizabeth Garrett Anderson Institute for Women's Health Elizabeth Benjamin, University College London Naveena Singh, Barts Health National Health Service Trust Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London Anne Dawnay, University College London Hospital James Mackay, The University College London Cancer Institute, University of Manchester, St Mary's Hospital Manchester, Southampton General Hospital, Massachusetts General Hospital and Harvard Medical School, University of New South Wales Australia
Usha MenonUniversity College London Elizabeth Garrett Anderson Institute for Women's Health Elizabeth Benjamin, University College London Naveena Singh, Barts Health National Health Service Trust Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London Anne Dawnay, University College London Hospital James Mackay, The University College London Cancer Institute, University of Manchester, St Mary's Hospital Manchester, Southampton General Hospital, Massachusetts General Hospital and Harvard Medical School, University of New South Wales Australia
  • 1 - 5

Datasets

Release 1.2